Navigation Links
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis
Date:9/21/2008

-- Study meets primary endpoint by demonstrating significant effect of new formulation of Rebif(R) on disease activity as measured by MRI after 16

weeks of treatment

-- Data presented at late-breaking session of the World Congress on

Treatment and Research in Multiple Sclerosis in Montreal, Canada

GENEVA, Sept. 22 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary endpoint. The primary objective of the study was to evaluate the efficacy of the new formulation of Rebif(R), compared to placebo, in patients with relapsing-remitting multiple sclerosis (RRMS) and active disease by means of magnetic resonance imaging (MRI) at the end of 16 weeks of treatment. The 16- week study results show that the mean number of combined unique active brain MRI lesions per patient was reduced by 69% in patients treated with the new formulation of Rebif(R) compared with those receiving placebo, a statistically significant result (p<0.001). These data were presented at the late-breaking session of the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada.

"Patients who received Rebif(R) experienced far fewer new active brain MRI lesions than the placebo group after 16 weeks of treatment," said Dr. Mark Freedman, Professor of Neurology at the University of Ottawa, Director of the MS Research Clinic at the Ottawa Hospital, and an investigator of the IMPROVE trial. "These data demonstrate a significant effect of the new formulation of Rebif(R) on disease activity and provide further evidence of its benefit in treating patients with relapsing-remitting multiple sclerosis."

The IMPROVE study is a two-arm, randomized, double-blind, controlled, multicenter, international Phase IIIb study to evaluate the efficacy, safety and tolerability of the new
'/>"/>

SOURCE Merck Serono
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Brooke Franchise Corporation Announces Selected July Results
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
5. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
6. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
7. Martek Announces Third Quarter 2007 Financial Results
8. MDS Reports Third Quarter 2007 Results
9. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
10. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015 Ticket Down is a reputable source ... at the Moda Center. After being away from the ... showing no signs of letting up on his “Garth Brooks ... his wife, Trisha Yearwood, to venues around the United States. ... critically acclaimed tour to the Moda Center in Portland, OR. ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance its ... two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D and ... Pavlath, Ph.D, who joined MDA late last year as ... will lead MDA as it accelerates new front-line discovery ... of neuromuscular and motor neuron diseases. , ...
(Date:3/6/2015)... US Sports Football Camps expands its ... two non-contact specialty camps and one contact football camp. ... Training, located at Bowie State University and Riverdale Baptist ... skills, speed and strength of football athletes. The contact ... Marvin Graves, former quarterback in the Canadian Football League, ...
(Date:3/6/2015)... Johnson & Johnson and Ethicon were hit ... 2015 in Superior Court in the State of California ... of 12 awarded Mrs. Perry $700,000 in actual damages ... Ethicon TVT Abbrevo plastic sling for stress urinary incontinence. ... awarded $5 million in punitive damages. , According to ...
(Date:3/6/2015)... 06, 2015 Jvion, the Atlanta-based ... of a Clostridium Difficile (C Diff) predictive use ... Diff use case is the latest in a ... acquired infections, chronic conditions, and individual illnesses. Using ... Diff solution flags at risk individuals to help ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... Article Reveals Intensive Case Management Helps Substance-Abusing Women ... Jan. 29 A new approach to helping ... and addiction as a chronic disease promises better ... that focus on employment first, according to ...
... National Heart, Lung, and Blood InstituteATLANTA, Jan. 29 For ... as its heart health ambassador in support of The ... National Heart, Lung, and Blood Institute (NHLBI) to educate women ... involvement in The Heart Truth will include sponsorship ...
... Cooling Therapy for Cardiac PatientsSAN DIEGO, Jan. 29 ... its operating unit InnerCool Therapies today reported on ... leading the charge and adopting therapeutic hypothermia protocols ... recommend that cardiac arrest patients be quickly cooled, ...
... U.S. Establishes ,Diabetes National Alliance, of Healthcare Professionals ... in U.S.BRIDGEWATER, N.J., Jan. 29 ... Diabetes National Alliance to address the growing diabetes ... with information on the standard of care for ...
... Harrisburg, PA-based national dental insurer United Concordia Companies, Inc. has renamed ... Claim, to better communicate the Web-based nature of the service.The online ... , Free electronic claims ... Real-time explanations of benefits (EOBs) , ...
... Jan. 29 AGA Medical Corporation (AGA) today,announced ... ruling by the German court of appeals over ... and notified Occlutech of the,amount of damages that ... court,s,ruling. After learning that Occlutech has terminated all ...
Cached Medicine News:Health News:CASA* Evaluation of Welfare Demonstration Program in New Jersey Finds Effective Approach to Addiction Recovery and Employment 2Health News:CASA* Evaluation of Welfare Demonstration Program in New Jersey Finds Effective Approach to Addiction Recovery and Employment 3Health News:CASA* Evaluation of Welfare Demonstration Program in New Jersey Finds Effective Approach to Addiction Recovery and Employment 4Health News:CASA* Evaluation of Welfare Demonstration Program in New Jersey Finds Effective Approach to Addiction Recovery and Employment 5Health News:Video: Diet Coke and Heidi Klum Use Their 'Charm' to Raise Awareness of Women's Heart Health 2Health News:Video: Diet Coke and Heidi Klum Use Their 'Charm' to Raise Awareness of Women's Heart Health 3Health News:Video: Diet Coke and Heidi Klum Use Their 'Charm' to Raise Awareness of Women's Heart Health 4Health News:Cardium's InnerCool Reports on Expanding Use of Therapeutic Hypothermia 2Health News:Cardium's InnerCool Reports on Expanding Use of Therapeutic Hypothermia 3Health News:Cardium's InnerCool Reports on Expanding Use of Therapeutic Hypothermia 4Health News:Cardium's InnerCool Reports on Expanding Use of Therapeutic Hypothermia 5Health News:Cardium's InnerCool Reports on Expanding Use of Therapeutic Hypothermia 6Health News:Cardium's InnerCool Reports on Expanding Use of Therapeutic Hypothermia 7Health News:Cardium's InnerCool Reports on Expanding Use of Therapeutic Hypothermia 8Health News:Cardium's InnerCool Reports on Expanding Use of Therapeutic Hypothermia 9Health News:Cardium's InnerCool Reports on Expanding Use of Therapeutic Hypothermia 10Health News:Alliance of Experts Created to Help Raise Awareness of Best Practices in Diabetes Treatment 2Health News:Alliance of Experts Created to Help Raise Awareness of Best Practices in Diabetes Treatment 3Health News:Speed eClaim Helps National Dental Insurer United Concordia Process Claims Quickly, Efficiently and Electronically 2Health News:AGA Medical Corporation Begins Proceedings Against Occlutech to Recover Damages 2
(Date:3/5/2015)... 5, 2015  BioPhotas, Inc., an FDA registered medical ... photo-therapeutic technologies to treat skin, muscle and joint conditions, ... Fi Fund to provide BioPhotas, flagship product, the ... management solutions.  Commenting on the alliance, ... used the Celluma at the Warrior Hope and Care ...
(Date:3/5/2015)... 2015  Medical Diagnostic Laboratories, L.L.C., (MDL), a ... state-of-the-art, automated DNA-based molecular analyses, announces that it ... which utilizes cutting edge technology, including next- generation ... 12,000 women are diagnosed with cervical cancer in ... Human Papillomaviruses (HPV) are a group of more ...
(Date:3/5/2015)...  ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... the approved abbreviated new drug application ("ANDA") for ... previously marketed by Teva Pharmaceuticals.  According to IMS ... approximately $39 million in 2014.   ... of ANI Pharmaceuticals, stated, "This acquisition further expands ...
Breaking Medicine Technology:BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3
... Brilliance 64-channel configuration breaks through previous ... volume, thin-slice coverage to improve diagnostic ... ,With 40mm of thin-slice coverage, the ... allowing for unprecedented coronary artery evaluation. ...
Assay for Anti-HTLV-I and Anti-HTLV-II...
InBios' Trypanosoma cruzi (chagas disease) is an ELISA system for the detection of antibodies to T.cruzi derived TcF antigen in human serum or plasma This test is intended for professional in vitro d...
... most flexible meter for Point ... hospitals. Accu-Chek Inform System offers ... is the only Point of ... for the entry and automatic ...
Medicine Products: